XNYS · Healthcare · Health Information Services
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
General Counsel Josh Faddis retiring in November amid **$0.22 EPS beat** and 16% revenue growth. Life sciences software leader maintains strong execution despite leadership transition.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | Q1 2027 | 2.02 | 2.24 | +10.89% | $882.9M | ✅ Beat | — | — | — |
| 2026-03-04 | Q4 2026 | 1.71 | 2.06 | +20.47% | $836.0M | ✅ Beat | +11.31% | -0.74% | -7.69% |
| 2025-11-20 |
| Q3 2026 |
| 1.71 |
| 2.04 |
| +19.30% |
| $811.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-27 | Q2 2026 | 1.68 | 1.99 | +18.45% | $789.1M | ✅ Beat | -4.28% | -7.71% | -1.13% |
| 2025-05-28 | Q1 2026 | 1.74 | 1.97 | +13.22% | $759.0M | ✅ Beat | — | — | — |
| 2025-03-05 | Q4 2025 | 1.58 | 1.74 | +10.13% | $720.9M | ✅ Beat | — | — | — |
| 2024-12-05 | Q3 2025 | 1.58 | 1.75 | +10.76% | $699.2M | ✅ Beat | — | — | — |
| 2024-08-28 | Q2 2025 | 1.52 | 1.62 | +6.58% | $676.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.